Novavax (STU:NVV1) Total Tax Payable : €0.0 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Novavax Total Tax Payable?

Novavax's Total Tax Payable for the quarter that ended in Mar. 2024 was €0.0 Mil.

Novavax Total Tax Payable Historical Data

The historical data trend for Novavax's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Total Tax Payable Chart

Novavax Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Tax Payable

Get a 7-Day Free Trial

Novavax Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Tax Payable	Get a 7-Day Free Trial															-	-	-	-	-

Novavax Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Novavax Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Novavax's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Novavax (STU:NVV1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (STU:NVV1) » Definitions » Total Tax Payable

Comparable Companies

Traded in Other Exchanges

NVAX:USA NVAX:Mexico NVV1:Germany

Address

21 Firstfield Road, Gaithersburg, MD, USA, 20878

Website

https://www.novavax.com

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

Novavax (STU:NVV1) Headlines

No Headlines